Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia

Background & Aims. This paper presents the results of the observational study of ibrutinib in patients with chronic lymphocytic leukemia (CLL), conducted in SP Botkin Municipal Clinical Hospital. The main objective was the analysis of complications of ibrutinib and identification of factors, influen...

Бүрэн тодорхойлолт

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Evgenii Aleksandrovich Nikitin, E. A. Dmitrieva, M. A. Panteleev, E. I. Emelina, V. L. Ivanova, Yu. B. Kochkareva, E. G. Arshanskaya, I. E. Lazarev, E. E. Markova, L. A. Mukha, N. G. Novitskaya, M. M. Pankrashkina, V. V. Glazunova, A. V. Shubina, S. A. Chernysh, N. K. Khuazheva, E. V. Naumova, S. A. Lugovskaya, M. E. Pochtar’, T. N. Obukhova, O. Yu. Vinogradova, G. E. Gendlin, V. V. Ptushkin
Формат:	Artigo
Хэл сонгох:	Russo
Хэвлэсэн:	Practical Medicine Publishing House 2017-07-01
Цуврал:	Клиническая онкогематология
Нөхцлүүд:	chronic lymphocytic leukemia del 17p tp53 refractory cll ibrutinib bleeding atrial fibrillation
Онлайн хандалт:	https://bloodjournal.ru/index.php/coh/article/view/424
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia

Ижил төстэй зүйлс